Mesoblast pays $50mm up front for Osiris’ stem cell assets

Mesoblast International SARL, a subsidiary of Australian biotech Mesoblast Ltd., acquired the culture-expanded mesenchymal stem cell (ceMSC) business of Osiris Therapeutics Inc. (tissue repair products and adult stem cell candidates) for $50mm up front, of which $35mm will be paid in cash ($20mm upon deal closing and $15mm in six months) and $15mm in Mesoblast stock (approximately 2.8mm shares based on Mesoblast’s 10-day average). Mesoblast takes ownership of 110 globally issued patents--including 48 in the US, 21 in Europe, 9 in Japan, and 32 in the rest of the world, encompassing composition-of-matter, uses, and methods claims with protection to 2025--plus patent applications, and clinical data from more than 1,500 patients.